Biologics Swing For The Fences: Payer Perspectives On Antibodies In Primary Care
Companies with large-molecule expertise increasingly are eyeing primary care markets, confident that improvements in safety and efficacy will make them competitive with oral standards of care.
You may also be interested in...
The Bothell, Wash.-based antibody developer will study a Phase II interleukin-6 inhibitor in cancer indications, and will bring a new migraine drug into the clinic. The IL-6 drug is already partnered with BMS in a lucrative deal for autoimmune indications.
H.I.G. Capital announced the closing of BioVentures II, a diversified life science venture fund focusing on drugs, medical devices, and diagnostics.
AstraZeneca PLC has operated Medimmune as an independent R&D subsidiary since 2007, with Centers of Excellence organized around large molecules in targeted therapeutic areas. The company retains small molecule development under the AZ umbrella, leading to what some might refer to as friendly" co-opetition."